Advertisement

Heart Failure Reviews

, Volume 23, Issue 4, pp 563–571 | Cite as

Anticoagulation in atrial fibrillation with heart failure

  • Lei Zhao
  • William Y. S. Wang
  • Xinchun Yang
Article
  • 450 Downloads

Abstract

Heart failure (HF) and atrial fibrillation (AF) frequently coexist, and they can beget one another due to similar factors and shared pathophysiology. These pathophysiologic changes promote the episodes of AF, while they in turn predispose to the exacerbation of HF. In this review, we will discuss pathophysiological mechanisms shared by AF and HF. Patients with concomitant HF and AF are at a particularly high risk of thromboembolism, which contribute to even worse symptoms and poorer prognosis. Vitamin K antagonists (VKA) (warfarin) were the traditional medication in AF patients for the prevention of stroke, whereas the advance of novel non-VKA oral anticoagulants (NOACs) (dabigatran, apixaban, rivaroxaban, and edoxaban) is challenging these standard prescriptions. NOACs’ potential advantages over warfarin, including fixed dosing regimens, wide therapeutic window, and more sustained anticoagulant response, promote clinicians to consider these novel agents in the first place. However, some data suggested patients with AF and HF may receive different therapeutic response than those with AF alone in anticoagulant treatment. Accordingly, we aim to assess the potential role of oral anticoagulants, especially NOACs, in the management of patients with concomitant AF and HF.

Keywords

Atrial fibrillation Heart failure Anticoagulants 

References

  1. 1.
    Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–2375CrossRefPubMedGoogle Scholar
  2. 2.
    Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920–2925CrossRefPubMedGoogle Scholar
  3. 3.
    Maisel WH, Stevenson LW (2003) Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91:2D–8DCrossRefPubMedGoogle Scholar
  4. 4.
    Luong C, Barnes ME, Tsang TSM (2014) Atrial fibrillation and heart failure: cause or effect? Curr Heart Fail Rep 11:463–470CrossRefPubMedGoogle Scholar
  5. 5.
    Pulignano G, Del Sindaco D, Tinti MD, Tolone S, Minardi G, Lax A, Uguccioni M (2016) Atrial fibrillation management in older heart failure patients: a complex clinical problem. Heart Int 11:e41–e49CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Harel Z, Chertow GM, Shah PS, Harel S, Dorian P, Yan AT, Saposnik G, Sood MM, Molnar AO, Perl J, Wald RM, Silver S, Wald R (2017) Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis. Can J Cardiol 33:737–746CrossRefPubMedGoogle Scholar
  7. 7.
    Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace 14:1385–1413CrossRefPubMedGoogle Scholar
  8. 8.
    Isnard R, Bauer F, Cohen-Solal A, Damy T, Donal E, Galinier M, Hagège A, Jourdain P, Leclercq C, Sabatier R, Trochu J, Cohen A (2016) Non-vitamin K antagonist oral anticoagulants and heart failure. Arch Cardiovasc Dis 109:641–650CrossRefPubMedGoogle Scholar
  9. 9.
    Brown LAE, Boos CJ (2017) Atrial fibrillation and heart failure: factors influencing the choice of oral anticoagulant. Int J Cardiol 227:863–868CrossRefPubMedGoogle Scholar
  10. 10.
    Ferreira J, Santos M (2015) Heart failure and atrial fibrillation: from basic science to clinical practice. Int J Mol Sci 16:3133–3147CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, Ellinor PT, Cheng S, Vasan RS, Lee DS, Wang TJ, Levy D, Benjamin EJ, Ho JE (2016) Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133:484–492CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ (2016) Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol 13:131–147CrossRefPubMedGoogle Scholar
  13. 13.
    Oren O, Goldberg S (2017) Heart failure with preserved ejection fraction: diagnosis and management. Am J Med 130:510–516CrossRefPubMedGoogle Scholar
  14. 14.
    Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D (2009) Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation 119:3070–3077CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L (2012) Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 14:295–301CrossRefPubMedGoogle Scholar
  16. 16.
    Mueller K, Heinzmann D, Klingel K, Fallier-Becker P, Kandolf R, Kilias A, Walker-Allgaier B, Borst O, Kumbrink J, Kirchner T, Langer H, Geisler T, Schreieck J, Gramlich M, Gawaz M, Seizer P (2017) Histopathological and immunological characteristics of tachycardia-induced cardiomyopathy. J Am Coll Cardiol 69:2160–2172CrossRefPubMedGoogle Scholar
  17. 17.
    Lee PK, Anter E (2013) Atrial fibrillation and heart failure: a review of the intersection of two cardiac epidemics. J Atr Fibrillation 6:751Google Scholar
  18. 18.
    Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM (1997) Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 29:709–715CrossRefPubMedGoogle Scholar
  19. 19.
    Hartupee J, Mann DL (2017) Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol 14:30–38CrossRefPubMedGoogle Scholar
  20. 20.
    Florea VG, Cohn JN (2014) The autonomic nervous system and heart failure. Circ Res 114:1815–1826CrossRefPubMedGoogle Scholar
  21. 21.
    Antoine S, Vaidya G, Imam H, Villarreal D (2017) Pathophysiologic mechanisms in heart failure: role of the sympathetic nervous system. Am J Med Sci 353:27–30CrossRefPubMedGoogle Scholar
  22. 22.
    Floras JS, Ponikowski P (2015) The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. Eur Heart J 36:1974–1982CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wang W, Schultz HD, Ma R (2001) Volume expansion potentiates cardiac sympathetic afferent reflex in dogs. Am J Physiol Heart Circ Physiol 280:H576–H581CrossRefPubMedGoogle Scholar
  24. 24.
    Ng J, Villuendas R, Cokic I, Schliamser JE, Gordon D, Koduri H, Benefield B, Simon J, Murthy SN, Lomasney JW, Wasserstrom JA, Goldberger JJ, Aistrup GL, Arora R (2011) Autonomic remodeling in the left atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation. Circ Arrhythm Electrophysiol 4:388–396CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Masuda M, Yamada T, Mizuno H, Minamiguchi H, Konishi S, Ohtani T, Yamaguchi O, Okuyama Y, Uematsu M, Sakata Y (2015) Impact of atrial fibrillation ablation on cardiac sympathetic nervous system in patients with and without heart failure. Int J Cardiol 199:65–70CrossRefPubMedGoogle Scholar
  26. 26.
    Perera RK, Sprenger JU, Steinbrecher JH, Hubscher D, Lehnart SE, Abesser M, Schuh K, El-Armouche A, Nikolaev VO (2015) Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of beta-adrenoceptor-stimulated contractility in early cardiac hypertrophy. Circ Res 116:1304–1311CrossRefPubMedGoogle Scholar
  27. 27.
    Triposkiadis F, Pieske B, Butler J, Parissis J, Giamouzis G, Skoularigis J, Brutsaert D, Boudoulas H (2016) Global left atrial failure in heart failure. Eur J Heart Fail 18:1307–1320CrossRefPubMedGoogle Scholar
  28. 28.
    Jalife J, Kaur K (2015) Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovas Med 25:475–484CrossRefGoogle Scholar
  29. 29.
    Patel RB, Vaduganathan M, Shah SJ, Butler J (2017) Atrial fibrillation in heart failure with preserved ejection fraction: insights into mechanisms and therapeutics. Pharmacol Therapeut 176:32–39CrossRefGoogle Scholar
  30. 30.
    Andrade J, Khairy P, Dobrev D, Nattel S (2014) The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 114:1453–1468CrossRefPubMedGoogle Scholar
  31. 31.
    Nattel S, Dobrev D (2016) Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. Nat Rev Cardiol 13:575–590CrossRefPubMedGoogle Scholar
  32. 32.
    Beuckelmann DJ, Nabauer M, Erdmann E (1992) Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85:1046–1055CrossRefPubMedGoogle Scholar
  33. 33.
    Ohkusa T, Ueyama T, Yamada J, Yano M, Fujumura Y, Esato K, Matsuzaki M (1999) Alterations in cardiac sarcoplasmic reticulum Ca2+ regulatory proteins in the atrial tissue of patients with chronic atrial fibrillation. J Am Coll Cardiol 34:255–263CrossRefPubMedGoogle Scholar
  34. 34.
    Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, Nattel S (2000) Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101:2631–2638CrossRefPubMedGoogle Scholar
  35. 35.
    Gurbel PA, Tantry US (2014) Antiplatelet and anticoagulant agents in heart failure. JACC: Heart Fail 2:1–14Google Scholar
  36. 36.
    Naccarelli GV, Panaccio MP, Cummins G, Tu N (2012) CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. Am J Cardiol 109:1526–1533CrossRefPubMedGoogle Scholar
  37. 37.
    Cleland JG, Mumtaz S, Cecchini L (2012) Role of antithrombotic agents in heart failure. Curr Cardiol Rep 14:314–325CrossRefPubMedGoogle Scholar
  38. 38.
    Boos CJ, Nam M, Camm AJ (2014) Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev 19:391–401CrossRefPubMedGoogle Scholar
  39. 39.
    Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903–1912CrossRefPubMedGoogle Scholar
  40. 40.
    Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370:493–503CrossRefPubMedGoogle Scholar
  41. 41.
    Boos CJ, Brown L (2016) Anticoagulation in atrial fibrillation and chronic heart failure. Curr Opin Cardiol 31:229–234CrossRefPubMedGoogle Scholar
  42. 42.
    (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457Google Scholar
  43. 43.
    Apostolakis S, Sullivan RM, Olshansky B, Lip G (2013) Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 144:1555–1563CrossRefPubMedGoogle Scholar
  44. 44.
    Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747CrossRefPubMedGoogle Scholar
  45. 45.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  46. 46.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 365:883–891CrossRefPubMedGoogle Scholar
  47. 47.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMedGoogle Scholar
  48. 48.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104CrossRefPubMedGoogle Scholar
  49. 49.
    Antonijevic NM, Zivkovic ID, Jovanovic LM, Matic DM, Kocica MJ, Mrdovic IB, Kanjuh VI, Culafic MD (2017) Dabigatran—metabolism, pharmacologic properties and drug interactions. Curr Drug Metab 18:622–635CrossRefPubMedGoogle Scholar
  50. 50.
    Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA, Yusuf S, Wallentin L (2013) Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 15:1053–1061CrossRefPubMedGoogle Scholar
  51. 51.
    Mumoli N, Mastroiacovo D, Tamborini-Permunian E, Vitale J, Giorgi-Pierfranceschi M, Cei M, Dentali F (2017) Dabigatran in nonvalvular atrial fibrillation. J Cardiovasc Med 18:467–477CrossRefGoogle Scholar
  52. 52.
    Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817CrossRefPubMedGoogle Scholar
  53. 53.
    McMurray JJV, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, Bartunek J, Commerford P, Oh BH, Harjola VP, Al-Khatib SM, Hanna M, Alexander JH, Lopes RD, Wojdyla DM, Wallentin L, Granger CB (2013) Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 6:451–460CrossRefPubMedGoogle Scholar
  54. 54.
    Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V (2010) Rivaroxaban (2010) a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 30:376–381CrossRefPubMedGoogle Scholar
  55. 55.
    van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Califf RM, Fox KAA, Mahaffey KW (2013) Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 6:740–747CrossRefPubMedGoogle Scholar
  56. 56.
    Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, Moccetti T, Mitrovic V, Shi M, Mercuri M, Antman EM, Braunwald E (2016) Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail 18:1153–1161CrossRefPubMedGoogle Scholar
  57. 57.
    Poulakos M, Walker JN, Baig U, David T (2017) Edoxaban: a direct oral anticoagulant. Am J Health Syst Pharm 74:117–129CrossRefPubMedGoogle Scholar
  58. 58.
    Lip GYH, Agnelli G (2014) Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 35:1844–1855CrossRefPubMedGoogle Scholar
  59. 59.
    Ahmad Y, Lip GY, Apostolakis S (2012) New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Rev Cardiovasc Ther 10:1471–1480CrossRefPubMedGoogle Scholar
  60. 60.
    Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH (2015) Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 17:1192–1200CrossRefPubMedGoogle Scholar
  61. 61.
    Savarese G, Giugliano RP, Rosano GMC, McMurray J, Magnani G, Filippatos G, Dellegrottaglie S, Lund LH, Trimarco B, Perrone-Filardi P (2016) Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC: Heart Fail 4:870–880Google Scholar
  62. 62.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JJ, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1–e76CrossRefPubMedGoogle Scholar
  63. 63.
    Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J (2012) Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ 15:776–785CrossRefPubMedGoogle Scholar
  64. 64.
    Jegathisawaran J, Holbrook A, Bowen JM, Burke N, Campbell K, Tarride JE (2017) What influences the cost effectiveness of dabigatran versus warfarin for stroke prevention in atrial fibrillation: a systematic review. J Popul Ther Clin Pharmacol 24:e1–e20PubMedGoogle Scholar
  65. 65.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA (2016) Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 5:e3725Google Scholar
  66. 66.
    Lai CL, Chen HM, Liao MT, Lin TT, Chan KA (2017) Comparative effectiveness and safety of dabigatran and rivaroxaban in atrial fibrillation patients. J Am Heart Assoc 6:e005362CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Sheerin NJ, Newton PJ, Macdonald PS, Leung DYC, Sibbritt D, Spicer ST, Johnson K, Krum H, Davidson PM (2014) Worsening renal function in heart failure: the need for a consensus definition. Int J Cardiol 174:484–491CrossRefPubMedGoogle Scholar
  68. 68.
    Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J (2007) High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13:422–430CrossRefPubMedGoogle Scholar
  69. 69.
    Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt F, Veltkamp R, Lip G (2017) Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 38:860–868CrossRefPubMedGoogle Scholar
  70. 70.
    Di Lullo L, Ronco C, Cozzolino M, Russo D, Russo L, Di Iorio B, De Pascalis A, Barbera V, Galliani M, Vitaliano E, Campana C, Santoboni F, Bellasi A (2017) Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thromb Res 155:38–47CrossRefPubMedGoogle Scholar
  71. 71.
    Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GYH, Larsen TB (2017) Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 356:j510CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Samuelson BT, Cuker A (2017) Measurement and reversal of the direct oral anticoagulants. Blood Rev 31:77–84CrossRefPubMedGoogle Scholar
  73. 73.
    Siegal DM, Cuker A (2014) Reversal of target-specific oral anticoagulants. Drug Discov Today 19:1465–1470CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Pollack CJ, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Cardiology, Beijing Chaoyang HospitalCapital Medical UniversityBeijingChina
  2. 2.Department of Cardiology, Princess Alexandra HospitalThe University of QueenslandBrisbaneAustralia

Personalised recommendations